- Home
- HUM vs TAK Comparison
HUM vs TAK Comparison
Compare HUM & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUM | TAK |
|---|---|---|
| Founded | 1961 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.0B | 55.1B |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | HUM | TAK |
|---|---|---|
| Price | $388.77 | $17.62 |
| Analyst Decision | Hold | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $238.65 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 3.9M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | 1.46% | ★ 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.83 | N/A |
| Revenue | ★ $129,664,000,000.00 | N/A |
| Revenue This Year | $26.15 | $0.16 |
| Revenue Next Year | $6.07 | $1.22 |
| P/E Ratio | ★ $39.16 | $41.25 |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $163.11 | $12.99 |
| 52 Week High | $428.88 | $18.90 |
Technical Indicators
Market Signals| Indicator | HUM | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 61.18 |
| Support Level | $385.22 | $16.29 |
| Resistance Level | $421.94 | $17.83 |
| Average True Range (ATR) | 16.76 | 0.25 |
| MACD | 0.75 | 0.01 |
| Stochastic Oscillator | 81.53 | 85.95 |
Price Performance
Historical ComparisonAbout HUM Humana Inc.
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.